Pataday

Pataday is a brand name of olopatadine ophthalmic, approved by the FDA in the following formulation(s):

PATADAY (olopatadine hydrochloride - solution/drops; ophthalmic)

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: December 22, 2004
  
  Strength(s): EQ 0.2% BASE ^[RLD]

Has a generic version of Pataday been approved?

No. There is currently no therapeutically equivalent version of Pataday available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pataday. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Topical ophthalmic formulations for treating allergic eye diseases
  Patent 5,641,805
  Issued: June 24, 1997
  Inventor(s): Hayakawa; Eiji & Nakakura; Masashi & Robertson; Stella M. & Yanni; John Michael
  Assignee(s): Alcon Laboratories, Inc.
  Kyowa Hakko Kogyo Co. Ltd.
  Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
  
  Patent expiration dates:
  
  
  • June 6, 2015
    
    ✓ 
    Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
  
  
  
  • December 6, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Olopatadine formulations for topical administration
  Patent 6,995,186
  Issued: February 7, 2006
  Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
  Assignee(s): Alcon, Inc.
  Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
  
  Patent expiration dates:
  
  
  • November 12, 2023
    
    ✓ 
    Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
    ✓ 
    Drug product
  
  
  
  • May 12, 2024
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Olopatadine formulations for topical administration
  Patent 7,402,609
  Issued: July 22, 2008
  Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
  Assignee(s): Alcon, Inc.
  Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
  
  Patent expiration dates:
  
  
  • June 19, 2022
    
    ✓ 
    Drug product
  
  
  
  • December 19, 2022
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Pataday Drops Consumer Information (Wolters Kluwer)
• Pataday Consumer Information (Cerner Multum)
• Pataday Advanced Consumer Information (Micromedex)
• Olopatadine Drops Consumer Information (Wolters Kluwer)
• Olopatadine ophthalmic Consumer Information (Cerner Multum)
• Olopatadine Ophthalmic Advanced Consumer Information (Micromedex)
• Olopatadine Hydrochloride AHFS DI Monographs (ASHP)